These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

503 related items for PubMed ID: 15582059

  • 1. Risk of cardiovascular events and rofecoxib: cumulative meta-analysis.
    Jüni P, Nartey L, Reichenbach S, Sterchi R, Dieppe PA, Egger M.
    Lancet; ; 364(9450):2021-9. PubMed ID: 15582059
    [Abstract] [Full Text] [Related]

  • 2. Rofecoxib for rheumatoid arthritis.
    Garner SE, Fidan DD, Frankish RR, Judd MG, Towheed TE, Wells G, Tugwell P.
    Cochrane Database Syst Rev; 2005 Jan 25; 2005(1):CD003685. PubMed ID: 15674912
    [Abstract] [Full Text] [Related]

  • 3. Selective COX-2 inhibition and cardiovascular effects: a review of the rofecoxib development program.
    Weir MR, Sperling RS, Reicin A, Gertz BJ.
    Am Heart J; 2003 Oct 25; 146(4):591-604. PubMed ID: 14564311
    [Abstract] [Full Text] [Related]

  • 4. Non-steroidal anti-inflammatory drugs (NSAIDs) for chronic non-cancer pain in children and adolescents.
    Eccleston C, Cooper TE, Fisher E, Anderson B, Wilkinson NM.
    Cochrane Database Syst Rev; 2017 Aug 02; 8(8):CD012537. PubMed ID: 28770976
    [Abstract] [Full Text] [Related]

  • 5. Cardiovascular thrombotic events in controlled, clinical trials of rofecoxib.
    Konstam MA, Weir MR, Reicin A, Shapiro D, Sperling RS, Barr E, Gertz BJ.
    Circulation; 2001 Nov 06; 104(19):2280-8. PubMed ID: 11696466
    [Abstract] [Full Text] [Related]

  • 6. Gastrointestinal tolerability and effectiveness of rofecoxib versus naproxen in the treatment of osteoarthritis: a randomized, controlled trial.
    Lisse JR, Perlman M, Johansson G, Shoemaker JR, Schechtman J, Skalky CS, Dixon ME, Polis AB, Mollen AJ, Geba GP, ADVANTAGE Study Group.
    Ann Intern Med; 2003 Oct 07; 139(7):539-46. PubMed ID: 14530224
    [Abstract] [Full Text] [Related]

  • 7. The Effects of cyclooxygenase-2 inhibitors and nonsteroidal anti-inflammatory therapy on 24-hour blood pressure in patients with hypertension, osteoarthritis, and type 2 diabetes mellitus.
    Sowers JR, White WB, Pitt B, Whelton A, Simon LS, Winer N, Kivitz A, van Ingen H, Brabant T, Fort JG, Celecoxib Rofecoxib Efficacy and Safety in Comorbidities Evaluation Trial (CRESCENT) Investigators.
    Arch Intern Med; 2005 Jan 24; 165(2):161-8. PubMed ID: 15668361
    [Abstract] [Full Text] [Related]

  • 8. Incidence of gastroduodenal ulcers in patients with rheumatoid arthritis after 12 weeks of rofecoxib, naproxen, or placebo: a multicentre, randomised, double blind study.
    Hawkey CJ, Laine L, Simon T, Quan H, Shingo S, Evans J, Rofecoxib Rheumatoid Arthritis Endoscopy Study Group.
    Gut; 2003 Jun 24; 52(6):820-6. PubMed ID: 12740337
    [Abstract] [Full Text] [Related]

  • 9. Risk of acute myocardial infarction and sudden cardiac death in patients treated with cyclo-oxygenase 2 selective and non-selective non-steroidal anti-inflammatory drugs: nested case-control study.
    Graham DJ, Campen D, Hui R, Spence M, Cheetham C, Levy G, Shoor S, Ray WA.
    Lancet; 2003 Jun 24; 365(9458):475-81. PubMed ID: 15705456
    [Abstract] [Full Text] [Related]

  • 10. Cardiovascular safety of lumiracoxib: a meta-analysis of all randomized controlled trials > or =1 week and up to 1 year in duration of patients with osteoarthritis and rheumatoid arthritis.
    Matchaba P, Gitton X, Krammer G, Ehrsam E, Sloan VS, Olson M, Mellein B, Hoexter G, Orloff J, Garaud JJ.
    Clin Ther; 2005 Aug 24; 27(8):1196-214. PubMed ID: 16199245
    [Abstract] [Full Text] [Related]

  • 11. The trade-off between cardiovascular and gastrointestinal effects of rofecoxib.
    Florentinus SR, Heerdink ER, de Boer A, van Dijk L, Leufkens HG.
    Pharmacoepidemiol Drug Saf; 2005 Jul 24; 14(7):437-41. PubMed ID: 15937867
    [Abstract] [Full Text] [Related]

  • 12. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis.
    Choi HK, Seeger JD, Kuntz KM.
    Am J Med; 2004 May 01; 116(9):621-9. PubMed ID: 15093759
    [Abstract] [Full Text] [Related]

  • 13. The upper gastrointestinal safety of rofecoxib vs. NSAIDs: an updated combined analysis.
    Watson DJ, Yu Q, Bolognese JA, Reicin AS, Simon TJ.
    Curr Med Res Opin; 2004 Oct 01; 20(10):1539-48. PubMed ID: 15462687
    [Abstract] [Full Text] [Related]

  • 14. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. VIGOR Study Group.
    Bombardier C, Laine L, Reicin A, Shapiro D, Burgos-Vargas R, Davis B, Day R, Ferraz MB, Hawkey CJ, Hochberg MC, Kvien TK, Schnitzer TJ, VIGOR Study Group.
    N Engl J Med; 2000 Nov 23; 343(21):1520-8, 2 p following 1528. PubMed ID: 11087881
    [Abstract] [Full Text] [Related]

  • 15. [Withdrawal of rofecoxib: a sign to be careful with coxibs in patients with increased cardiovascular risk].
    Bijlsma JW.
    Ned Tijdschr Geneeskd; 2004 Oct 30; 148(44):2162-4. PubMed ID: 15559407
    [Abstract] [Full Text] [Related]

  • 16. The cost effectiveness of rofecoxib and celecoxib in patients with osteoarthritis or rheumatoid arthritis.
    Maetzel A, Krahn M, Naglie G.
    Arthritis Rheum; 2003 Jun 15; 49(3):283-92. PubMed ID: 12794781
    [Abstract] [Full Text] [Related]

  • 17. Cardiovascular risk associated with celecoxib or etoricoxib: a meta-analysis of randomized controlled trials which adopted comparison with placebo or naproxen.
    De Vecchis R, Baldi C, Di Biase G, Ariano C, Cioppa C, Giasi A, Valente L, Cantatrione S.
    Minerva Cardioangiol; 2014 Dec 15; 62(6):437-48. PubMed ID: 25029569
    [Abstract] [Full Text] [Related]

  • 18. Effects of rofecoxib or naproxen vs placebo on Alzheimer disease progression: a randomized controlled trial.
    Aisen PS, Schafer KA, Grundman M, Pfeiffer E, Sano M, Davis KL, Farlow MR, Jin S, Thomas RG, Thal LJ, Alzheimer's Disease Cooperative Study.
    JAMA; 2003 Jun 04; 289(21):2819-26. PubMed ID: 12783912
    [Abstract] [Full Text] [Related]

  • 19. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial.
    Bresalier RS, Sandler RS, Quan H, Bolognese JA, Oxenius B, Horgan K, Lines C, Riddell R, Morton D, Lanas A, Konstam MA, Baron JA, Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators.
    N Engl J Med; 2005 Mar 17; 352(11):1092-102. PubMed ID: 15713943
    [Abstract] [Full Text] [Related]

  • 20. Rofecoxib for osteoarthritis.
    Garner SE, Fidan DD, Frankish R, Maxwell L.
    Cochrane Database Syst Rev; 2005 Jan 25; 2005(1):CD005115. PubMed ID: 15654705
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 26.